Gastric cancer is the cancer originating in the esophagus, esophagogastric junction and stomach.
Most of gastric cancers are adenocarcinomas, subdivided according to histological appearances into diffuse (undifferentiated) and intestinal (well differentiated) types.
It is the 4th most common cancer and the 2nd most common cause of cancer-related deaths worldwide.
Most common sites of gastric cancer are the proximal lesser curvature, cardia and esophagogastric junction.
The immune checkpoint inhibitor nivolumab yields long-term overall survival (OS) gains in treatment-experienced patients with gastric/gastroesophageal junction (G/GEJ), with the benefit most pronounced among those who show a complete (CR) or partial response (PR), according to the 2-year follow-up results of the phase III ATTRACTION-2a study.
Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.
Not only does washing away free tumour cells in the peritoneum with extensive intraoperative peritoneal lavage (EIPL) during gastrectomy confer no survival benefit nor prevent disease recurrence compared with surgery alone, it may come with an increased risk of side effects, according to the phase III EXPEL* study presented at GICS 2020.
Neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX) may be a suitable treatment measure for patients with advanced gastric or esophagogastric junction adenocarcinoma, according to the RESONANCE* trial presented at ASCO GI 2020.
Whether perioperative chemotherapy incorporating S-1 in the neoadjuvant setting provides better treatment outcomes than adjuvant chemotherapy postoperatively for patients with locally advanced gastric cancer (LAGC) was the topic of a lively discussion during the lunch forum session at the ISSPP 2019 Congress.
A neoadjuvant intraperitoneal and systemic chemotherapy (NIPS) comprising a triplet regimen of intraperitoneal docetaxel combined with intravenous cisplatin and oral S-1 was well tolerated with promising efficacy in patients who had gastric cancer with peritoneal carcinomatosis (PC), according to a presentation during the International Society for the Study of Pleura and Peritoneum (ISSPP) 2019 Congress held recently in Singapore
Helicobacter pylori treatment for 2 weeks and vitamin or garlic supplementation for 7 years have significantly lowered the risk of death due to gastric cancer during 22.3 years of follow-up, according to a recent study. H pylori treatment and vitamin supplementation are also associated with a reduced incidence of gastric cancer.
Use of docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as perioperative therapy in patients with locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma confers superior overall survival benefit compared with the standard of care epirubicin and cisplatin plus fluorouracil or capecitabine (ECF/ECX), according to the results of the open-label phase II/III FLOT4 trial.
Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.
Zolbetuximab monotherapy exhibits antitumour activity with acceptable tolerability profile in patients with Claudin 18.2 (CLDN18.2)-positive advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinomas, according to the results of a phase IIa trial.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.